Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
作者信息
DeGregorio Michael, Soe Lin, Wolf Michael
机构信息
1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
出版信息
J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15.
Abstract
摘要
相似文献
1
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.替西莫肽（L-BLP25）与安慰剂用于Ⅲ期非小细胞肺癌放化疗后的疗效比较（START）：一项随机、双盲、Ⅲ期试验
J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15.
2
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
3
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.替西莫肽作为免疫疗法用于日本不可切除的III期非小细胞肺癌患者的I/II期研究。
Lung Cancer. 2017 Mar;105:23-30. doi: 10.1016/j.lungcan.2017.01.007. Epub 2017 Jan 17.
4
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).结直肠癌肝转移灶切除术后使用替西莫肽进行辅助性MUC疫苗接种：一项随机、双盲、安慰剂对照、多中心AIO II期试验（LICC）
Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680.
5
Tecemotide: an antigen-specific cancer immunotherapy.替西莫肽：一种抗原特异性癌症免疫疗法。
Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836.
6
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.阐明基于替西莫肽（L-BLP25）的联合疗法的药效学。
Oncoimmunology. 2013 Oct 1;2(10):e26285. doi: 10.4161/onci.26285. Epub 2013 Sep 12.
7
L-BLP25: a peptide vaccine strategy in non small cell lung cancer.L-BLP25：非小细胞肺癌的一种肽疫苗策略
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4. doi: 10.1158/1078-0432.CCR-07-0213.
8
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.替西莫肽（L-BLP25）用于多发性骨髓瘤患者的粘蛋白1特异性活性癌症免疫治疗：一项探索性研究。
Hum Vaccin Immunother. 2014;10(11):3394-408. doi: 10.4161/hv.29918.
9
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.LICC 研究：L-BLP25 用于结直肠癌患者肝转移灶根治性切除术后的随机、安慰剂对照、多中心、多国、双盲 II 期临床试验。
BMC Cancer. 2012 Apr 11;12:144. doi: 10.1186/1471-2407-12-144.
10
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).在早期乳腺癌中的疗效和安全性的治疗性癌症疫苗替西莫肽（L-BLP25）：一项前瞻性、随机、新辅助 II 期研究（ABCSG 34）的结果。
Eur J Cancer. 2020 Jun;132:43-52. doi: 10.1016/j.ejca.2020.03.018. Epub 2020 Apr 20.
引用本文的文献
1
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort study.III期非小细胞肺癌根治性放化疗后的生存预测因素及复发模式——一项回顾性队列研究
Transl Lung Cancer Res. 2025 Jun 30;14(6):1972-1985. doi: 10.21037/tlcr-24-840. Epub 2025 Jun 24.
2
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.基于纳米载体的疫苗递送佐剂概述
Pharmaceutics. 2021 Mar 27;13(4):455. doi: 10.3390/pharmaceutics13040455.
3
Immunomodulatory Nanosystems.免疫调节纳米系统
Adv Sci (Weinh). 2019 Jun 21;6(17):1900101. doi: 10.1002/advs.201900101. eCollection 2019 Sep 4.
4
[Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer].[可切除的 IIIa/N2 期非小细胞肺癌治疗方式综述]
Zhongguo Fei Ai Za Zhi. 2019 Feb 20;22(2):111-117. doi: 10.3779/j.issn.1009-3419.2019.02.06.
5
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.用于个性化免疫疗法的新型癌症抗原：最新证据与临床潜力
Ther Adv Med Oncol. 2016 Jan;8(1):4-31. doi: 10.1177/1758834015615514.
6
Tecemotide: an antigen-specific cancer immunotherapy.替西莫肽：一种抗原特异性癌症免疫疗法。
Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836.
本文引用的文献
1
Lung cancer vaccines: current status and future prospects.肺癌疫苗：现状与未来前景。
Transl Lung Cancer Res. 2014 Feb;3(1):46-52. doi: 10.3978/j.issn.2218-6751.2013.12.01.
2
Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.顺铂联合替西莫肽免疫疗法在人 MUC1 转基因肺癌小鼠模型中的抗肿瘤作用。
Cancer Immunol Res. 2014 Jun;2(6):581-9. doi: 10.1158/2326-6066.CIR-13-0205. Epub 2014 Mar 10.
3
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.阐明基于替西莫肽（L-BLP25）的联合疗法的药效学。
Oncoimmunology. 2013 Oct 1;2(10):e26285. doi: 10.4161/onci.26285. Epub 2013 Sep 12.
4
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.PD-1 和 Tim-3 调节黑色素瘤疫苗诱导的肿瘤抗原特异性 CD8⁺ T 细胞的扩增。
Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.
5
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
6
The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.在靶向治疗时代，化疗在晚期非小细胞肺癌治疗中的持续作用。
J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S556-64. doi: 10.3978/j.issn.2072-1439.2013.08.47.
7
Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.L-BLP25抗原特异性肿瘤免疫疗法在新型人MUC1转基因肺癌小鼠模型中的抗肿瘤作用
J Transl Med. 2013 Mar 13;11:64. doi: 10.1186/1479-5876-11-64.
8
Immunogenic and tolerogenic cell death.免疫原性和耐受性细胞死亡
Nat Rev Immunol. 2009 May;9(5):353-63. doi: 10.1038/nri2545.
9
Impact of glycans on T-cell tolerance to glycosylated self-antigens.聚糖对T细胞对糖基化自身抗原耐受性的影响。
Immunol Cell Biol. 2008 Oct;86(7):574-9. doi: 10.1038/icb.2008.48. Epub 2008 Jul 15.
10
O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.O-连接聚糖通过抗原呈递细胞控制糖蛋白加工：一种研究树突状细胞加工MUC1分子层面的生化方法。
Eur J Immunol. 2003 Dec;33(12):3242-54. doi: 10.1002/eji.200324189.
Zotero 插件